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INTRODUCTION 
  Respiratory infections may be upper or lower respiratory tract 
infections. Lower respiratory tract infections include pneumonia, lung 
abscess, bronchitis, bronchiolitis etc. 
  Lower respiratory tract infections are the major cause of morbidity and 
mortality worldwide. They remain the leading cause of deaths among all 
infectious diseases and they account for 3.9 million deaths worldwide and 
6.9% of all deaths.[105] 
  Lower respiratory tract infections are particularly more common in 
immunocompromised patients like HIV patients, transplant recipients, 
patients with neoplasms etc. 
Although rapid determination of the etiologic agents is of paramount 
importance in managing respiratory infections, the responsible pathogens are 
not determined in as many as 50% of patients despite extensive diagnostic 
tests.[6] The specimens used for the diagnosis of lower respiratory tract 
infections can be sputum, endotracheal aspirate, transtracheal aspirations, 
bronchoscopy specimens, lung puncture or biopsy. 
Examination of sputum has been the primary means of diagnosis but 
the drawback is the difficulty of some patients to mobilize the lower 
respiratory secretions and the possible contamination of sputum with 
oropharyngeal flora.[101] Other procedures like transtracheal aspirate, lung 
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puncture or lung biopsy are highly invasive and can cause pneumothorax or 
bleeding. 
Bronchoscopic specimens include bronchial washings or aspirate, 
bronchoalveolar lavage, protected bronchial brush samples. Fiberoptic 
bronchoscopy is the technique frequently used for obtaining these respiratory 
specimens. 
Bronchial washings or aspirates can also be contaminated with upper 
respiratory tract flora but more relevant than sputa.                 
BAL is a deeper sampling of desquamated host cells and secretions 
and now reported to have considerable value in diagnosing pulmonary 
infections. The value of this technique in conjunction with quantitative 
cultures for the diagnosis of most of the major respiratory tract pathogens, 
including bacterial pneumonia, has been documented.[25,73] BAL is especially 
suitable for detecting cysts of Pneumocystis jirovecii, fungal elements and 
mycobacteria.[23,96] BAL has been shown to be a safe and practical method 
for diagnosing opportunistic pulmonary infections in immunocompromised 
patients.  
Bronchoalveolar lavage involves the injection of 30 to 50 ml of 
physiological saline through a fiberoptic bronchoscope and using the aspirate  
for smear preparation and culture. 
9 
 
  Direct microscopic evaluation of smears provide immediate 
information about the causative organism and is helpful in starting 
antimicrobial therapy, but culture of the microbial pathogens is considered to 
be the gold standard. Semi-quantitative or quantitative cultures of respiratory 
secretions obtained by alveolar lavage techniques have been recommended 
for the diagnosis of pneumonias particularly in intubated patients undergoing 
ventilation.[26] 
      Antimicrobial susceptibility tests are mandatory to monitor the 
efficiency of available antimicrobial agents and the emergence of drug 
resistance among bacterial and fungal isolates. 
      Considering the importance of bronchoalveolar lavage in the 
diagnosis of lower respiratory tract infections, the present study was 
conducted to identify the common aerobic bacterial and fungal isolates and 
their antimicrobial susceptibility profile in patients with respiratory 
infections attending a tertiary care hospital in Chennai. 
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AIM OF THE STUDY 
 
? To isolate and identify the common aerobic bacterial agents in 
bronchoalveolar lavage 
? To isolate the common fungal agents in bronchoalveolar lavage 
? To evaluate the sensitivity and resistance pattern of all the bacterial 
agents isolated 
? To study the sensitivity and resistance of the fungal isolates to the 
commonly used antifungal drugs 
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REVIEW OF LITERATURE 
         Lower respiratory tract is the part of the respiratory tract below the 
vocal cords. While often used as a synonym for pneumonia, the rubric 
of lower respiratory tract infection can also be applied to other types of 
infection including lung abscess, bronchiolitis, bronchitis etc.   
Bronchitis 
         Bronchitis can be classified as either acute or chronic. Most often 
acute bronchitis is caused by viral infection and hence antibiotic therapy is 
not indicated in immunocompetent individuals.[114,111] A small proportion of  
cases of acute bronchitis have a non viral cause. However, in the group with 
the more prolonged course, termed infectious bronchitis, Mycoplasma 
pneumoniae and Bordetella pertussis play a more important role. In 
adolescents and adults with prolonged cough, Bordetella.pertussis has been 
associated with 12% to 32% cases.[29] Chlamydia pneumoniae strain TWAR 
respiratory tract infections have also included cases with the clinical features 
of acute bronchitis.[60,59] 
       Chronic bronchitis is symptomatically similar to acute bronchitis, but 
more prolonged and less intense. Bacteria predominate, particularly 
Streptococcus pneumoniae, non-capsulated Haemophilus influenzae and 
Moraxella catarrhalis.[77] 
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Bronchiolitis 
        Bronchiolitis is an acute lower respiratory tract illness that occurs 
during the first 2 years of life. The syndrome is caused primarily by viral 
infections. The characteristic clinical manifestations include an acute onset 
of wheezing and hyperinflation, most commonly associated with cough, 
rhinorrhea, tachypnea and respiratory distress.[82] 
  Respiratory syncitial virus is clearly the major pathogen and the para 
influenza viruses are the second most commonly isolated agent with 
Parainfluenza type 3 predominantly.[67] Occasionally Mycoplasma 
pneumoniae may cause bronchiolitis.                    
Pneumonia 
  The symptoms of pneumonia were described by Hippocrates (c. 460 
BC – 370 BC). Hippocrates referred to pneumonia as a disease "named by 
the ancients." Maimonides (1138–1204 AD) observed "The basic symptoms 
which occur in pneumonia and which are never lacking are as follows: acute 
fever, sticking [pleuritic] pain in the side, short rapid breaths, serrated pulse 
and cough."  
    Bacteria were first seen in the airways of individuals who died 
from pneumonia by Edwin Klebs in 1875. Initial work identifying the two 
common bacterial causes ''Streptococcus pneumoniae'' and ''Klebsiella 
pneumoniae'' was performed by Carl Friedlander and Albert Frankel in 1882 
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and 1884, respectively. Friedlander's initial work introduced the Gram stain, 
a fundamental laboratory test still used to identify and categorize bacteria. 
Christian Gram's paper describing the procedure in 1884 helped differentiate 
the two different bacteria and showed that pneumonia could be caused by 
more than one microorganism. 
         Sir William Osler, known as "the father of modern medicine," 
appreciated the morbidity and mortality of pneumonia, describing it as the 
"captain of the men of death" in 1918, as it had overtaken tuberculosis as one 
of the leading causes of death in his time. However, several key 
developments in the 1900s improved the outcome for those with pneumonia. 
With the advent of penicillin and other antibiotics, modern surgical 
techniques, and intensive care in the twentieth century, mortality from 
pneumonia dropped precipitously in the developed world. Vaccination of 
infants against ''Haemophilus influenzae'' type b began in 1988 and led to a 
dramatic decline in cases shortly thereafter. Vaccination against 
''Streptococcus pneumoniae'' in adults began in 1977 and in children began 
in 2000, resulting in a similar decline. 
In the past, pneumonia was typically classified as community-
acquired, hospital-acquired, or ventilator-associated. Over the last decade or 
two, patients presenting to the hospital have often been found to be infected 
with multidrug-resistant (MDR) pathogens previously associated with 
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hospital-acquired pneumonia. Factors responsible for this phenomenon 
include the development and widespread use of potent oral antibiotics, 
earlier transfer of patients out of acute-care hospitals to their homes or 
various lower-acuity facilities, increased use of outpatient IV antibiotic 
therapy, general aging of the population, and more extensive 
immunomodulatory therapies.  
The potential involvement of these MDR pathogens has led to a 
revised classification system in which infection is categorized as either 
community-acquired pneumonia (CAP) or health care–associated pneumonia 
(HCAP), with subcategories of HCAP including hospital-acquired 
pneumonia (HAP) and ventilator-associated pneumonia (VAP).[66] 
  The aetiology of pneumonia varies according to whether it has been 
acquired in the community or in hospital and the risk factor present. Many of 
the bacteria found as colonizers of the upper respiratory tract have been 
implicated in pneumonia. Antibiotic treatment and hospitalization affect the 
colonizing flora, leading to an increase in number of aerobic gram negative 
bacilli.[92] 
   These factors affect the sensitivity and specificity of sputum culture as 
a diagnostic test and results must always be interpreted in the light of clinical 
information.[101] Sputum culture results are often unreliable and sensitivity of 
culture is poor for many pathogens, although culture and antibiotic 
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sensitivity may be of value in sputum specimen from patients with severe 
exacerbation of COPD.[62] 
1. Community Acquired Pneumonia: 
    The commonest cause of CAP is Streptococcus pneumoniae, which is 
responsible for up to 60% of cases in community based surveys and may be 
multi-drug resistant. It can affect individuals of any age, including those 
without known risk factors. Other bacterial pathogens tend to cause 
pneumonia in the presence of specific risk factors. Patients with COPD are 
additionally at risk of pneumonia caused by Haemophilus influenzae, and 
Moraxella catarrhalis as are patients infected with HIV. Staphylococcus 
aureus pneumonia occurs either in the context of recent influenza infection 
or, less commonly as a result of blood borne spread from a distant focus, 
COPD or aspiration. Aerobic Gram-negative rods are rare causes of 
community acquired pneumonia. Occasionally, Klebsiella pneumoniae, can 
cause pneumonia typically in patients with a history of alcohol abuse and 
homelessness (Friedlander’s pneumoniae). 
   Mycoplasma pneumoniae cause up to 20% of community acquired 
pneumonia, second only to Streptococcus pneumoniae. It tends to occur in 
epidemics every 4 to 5 yrs and affects younger age groups. Chlamydia 
pneumoniae is an exclusively human pathogen[53], but pneumonia caused by 
Chlamydia psittaci and Coxiella burnetii occurs in individuals with the 
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relevant exposure history (bird and farm animals). These agents are 
responsible for a minority of cases. Legionella pneumophila is a rare cause 
of outbreaks of community acquired pneumonia. 
2. Hospital acquired pneumonia: 
Hospital acquired pneumonia is the second commonest type of 
nosocomial infection. Risk is increased by the presence of underlying 
diseases and by various interventions and procedures. Mechanical ventilation 
is a major risk factor. Patients with critical illnesses requiring prolonged 
ventilation are susceptible to multi-resistant Pseudomonas aeruginosa and 
Acinetobacter species (eg. Acinetobacter baumanii). Aerobic Gram-negative 
bacilli, including members of the Enterobacteriaceae (such as Klebsiella and 
Enterobacter sp.) and Pseudomonas aeruginosa are implicated in up to 60% 
cases.[45] 
Lung abscess 
   Lung abscess results when microbial infection causes necrosis of the 
lung parenchyma producing one or more cavities. These cavities often 
communicate with large airways resulting in cough with purulent sputum. 
Although many organisms may produce lung abscess, most cases are due to 
anaerobic mouth flora and follow aspiration. 
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  The predominant organisms responsible for lung abscess are bacteria, 
specifically mouth anaerobes that are normal flora in the gingival 
crevices.[11] In the presence of periodontal disease, the gingival crevice 
deepens and fills with anaerobic gram-negative organisms.[110] Studies 
employing sample collection techniques that avoid contamination with oral 
flora combined with good anaerobic culture methods showed that anaerobes 
are found in about 90% of lung abscesses and are the only organisms present 
in about half of cases.[9] The most frequently isolated anaerobes are 
Peptostreptococcus spp., Fusobacterium nucleatum, and Prevotella 
melaninogenica.[83,40] 
   Monomicrobial lung abscess occasionally may be caused by bacteria 
including Staphylococcus aureus, enteric gram-negative rods such as 
Klebsiella spp., Pseudomonas aeruginosa, Burkholderia pseudomallei 
(melioidosis), Pasteurella multocida, group A streptococcus, Haemophilus 
influenzae types b and c, Legionella spp., Rhodococcus equi, Actinomyces 
spp., and Nocardia spp. Streptococcus pneumoniae, particularly type 3, has 
been reported to cause lung abscess, but cavitation in the setting of 
pneumococcal pneumonia may be due to concomitant infection with 
anaerobes.[81] Other organisms that can cause lung abscess include many 
fungi, mycobacterial species, and parasites (e.g., Paragonimus westermani, 
Entamoeba histolytica). 
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  Oropharyngeal colonization with P. aeruginosa, other aerobic gram-
negative rods, and, less often, S. aureus is a common event in hospitalized 
patients, particularly patients who receive ventilatory support. 
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Common Aetiological agents of Lower Respiratory Tract Infections 
 
 
A) BACTERIA 
 1)Streptococcus 
pneumoniae  
 2)Staphylococcus aureus 
 3)Haemophilus influenzae 
 4)Enterobacteriaciae 
    a) Escherichia coli 
    b) Klebsiella spp 
    c) Enterobacter spp 
    d) Serratia spp 
    e) Pseudomonas  
       aeruginosa 
 5)Mixed anaerobic bacteria 
  a) Bacterioides spp 
  b) Fusobacterium spp 
  c) Peptostreptococcus spp    
  d) Prevotella spp. 
  e) Peptococcus spp 
B) FUNGI 
 1) Aspergillus spp 
 2) Candida spp 
 3) Pneumocystis jirovecii 
 4) Histoplasma capsulatum 
 5) Cryptococcus neoformans 
 6) Coccidioides imitis               
C) VIRAL 
   1) Children 
a)Respiratory syncitial virus 
b)Para influenza viruses             
c) Influenza A virus 
   2) Adults 
  a) Influenza A virus 
  b) Influenza B viru 
  c) Adeno virus types 4&7  
                            
 
D) ATYPICAL 
 1) Mycoplasma pneumoniae 
 2) Chlamydophila psittaci          
 3) Chlamydophila pneumoniae  
 4) Legionella spp 
E) RICKETTSIAL 
  1) Coxiella burnetti 
  2) Rickettsia rickettsiae 
F) MYCOBACTERIAL 
  1)Mycobacterium                     
      tuberculosis 
  2) Non tuberculous                  
        mycobacteria 
G) PARASITIC 
  1) Ascaris lumbricoides 
  2) Strongyloides stercoralis 
  3) Toxoplasma gondii 
  4) Paragonimus westermanii 
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Fungal infections: 
  Invasive pulmonary aspergillosis is an increasingly common problem 
in hospitalized patients receiving corticosteroids, especially in patients who 
are immunocompromised and those with prior pulmonary disease. 
Aspergillus fumigatus is the commonest Aspergillus spp. to infect humans.[43] 
The use of galactomannan testing of serum and BAL increases the diagnostic 
yields, as do research studies using molecular detection methods.[44]  
Pulmonary manifestations in hosts without major impairment of cellular or 
humoral immunity include allergic bronchopulmonary aspergillosis in 
patients with asthma or cystic fibrosis, chronic cavitary pulmonary 
aspergillosis and single aspergilloma. 
  Pneumocystis jirovecii pneumonia is a frequent opportunistic infection 
among AIDS patients. HIV infected patients are at high risk of developing 
Pneumocystis pneumonia when the CD4+ count is below 250/mm3.[94] 
Diagnostic confirmation of PCP is achieved by microscopic detection of 
Pneumocystis jirovecii in respiratory specimens taken by expectoration, 
induced sputum, open-lung biopsy, transbronchial biopsy, bronchoscopy or 
bronchoalveolar lavage. 
 Some unusual fungal causes of lower respiratory tract infections are 
endemic to defined geographical areas. The diagnosis should be considered 
in travelers returning from endemic areas who present with respiratory 
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illness or pneumonia, particularly if they fail to respond to standard therapy. 
These infections include histoplasmosis caused by Histoplasma capsulatum, 
coccidioidomycosis caused by Coccidioidis immitis and Coccidioidis 
pedrosii and blastomycosis caused by Blastomyces dermatidis. Although 
these infections have distinguishing characteristics, it is often difficult to 
differentiate them clinically from other causes of respiratory infection, 
particularly in their early stages. Paracoccidioidomycosis caused by 
Paracoccidioides braziliensis usually causes asymptomatic primary 
pulmonary infection that may reactivate if immune function decline. 
    Cryptococcus neoformans is an unusual cause of pneumonia, usually 
in normal hosts and may be associated with meningitis. It has a world wide 
distribution. 
      Candida spp. are rare causes of lower respiratory tract infections. 
Occasionally infections occur as a result of hematogenous seeding. 
Diagnosis is difficult given that the airways may become colonized in 
compromised hosts treated with antibiotics. 
Mycobacterium tuberculosis: 
   Mycobacterium tuberculosis was discovered by Robert Koch in 1882. 
The 1990 World Health Organization report on the Global Burden of 
Disease ranked tuberculosis as the seventh most morbidity-causing disease 
in the world and expected to continue in the same position up to 2020.[87]  
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      The initial diagnostic approach to suspected cases of pulmonary 
tuberculosis is to demonstrate mycobacterium tuberculosis in stained smears 
of expectorated sputum. In most of the tuberculosis centers, even after 
meticulous search, the bacteriological positive yield from sputum is around 
16-50% large portion remain negative in spite of clinical profile and 
radiological lesions being consistent with diagnosis of pulmonary  
tuberculosis.[79] The transmission rate of sputum smear negative tuberculosis 
as compared to smear positive tuberculosis is reported as 22%.[42] It has been 
reported that 74% of them develop active tuberculosis in five years, if not 
treated.[68] 
  Culture of sputum for Acid Fast Bacilli takes long time and a reliable 
serological test is not yet available. In such a situation bronchoscopy has 
been tried for rapid diagnosis of tuberculosis in smear negative cases. 
Nocardia and Actinomyces infections[4,10,14] 
  Nocardiosis and Actinomycosis are rare conditions that may affect 
other systems apart from the lungs. 
      Nocardia spp. are most often seen in the lungs and cause necrotizing 
pneumonia. This is commonly associated with cavitation. It may also 
produce a slowly enlarging pulmonary nodule and pneumonia that is often 
associated with empyema. Actinomycetes spp. cause a thoracic infection that 
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may involve the lungs, pleura, mediastinum or chest wall. Aspiration of oral 
contents is a risk factor for the development of thoracic actinomycosis. 
Parasitic infections: 
   Several helminthic infections may give rise to the syndrome Tropical 
Pulmonary Eosinophilia, characterized by patchy pulmonary infiltrates and 
eosinophilia accompanied by symptoms of cough, fever and weight loss. 
These signs and symptoms are associated with passage of larval forms 
through the lungs and include Ascaris lumbricoides, Ankylostoma duodenale 
and Strongyloides stercoralis. The lung fluke, Paragonimus westermanii has 
a wide distribution and is particularly prevalent in the Far East, India and 
West Africa. Human infection is acquired by consumption of uncooked 
freshwater crabs or crayfish that harbor encysted metacercariae. Ova of 
Paragonimus westermanii are demonstrable in sputum.[86] 
LAB DIAGNOSIS OF LOWER RESPIRATORY INFECTION 
Sputum examination:       
 Microscopic examination and culture of expectorated sputum remain 
the mainstay of the laboratory evaluation of pneumonia despite ongoing 
controversy concerning their sensitivity and specificity.[116] However, lower 
respiratory tract secretions will be contaminated with the upper respiratory 
secretions especially saliva and will be contaminated with normal 
oropharyngeal flora as it passes through the mouth.[6,77] Some individuals 
24 
 
like HIV patients and children have difficulty in mobilizing the lower 
respiratory secretions. 
Endotracheal aspirate: 
 The lower respiratory tract may be sampled by introducing a catheter 
through the larynx into the trachea. Endotracheal aspirates can also be 
contaminated because oral secretions can dribble down the pathway of the 
endotracheal tube. This technique has not been widely adopted nowadays.[77] 
Transtracheal aspirates: 
    Transtracheal aspirates are obtained by inserting a small plastic 
catheter into the trachea via a needle previously inserted though the skin and 
cricothyroid membrane. This procedure has reduced chance of contamination 
with upper respiratory flora. But due to the invasive nature and too frequent 
complications, this technique is rarely used.  
Bronchoscopic techniques for the diagnosis of LRTI: 
    The protected specimen brush [PSB] and Bronchoalveolar lavage 
(BAL) are the two techniques that have evolved for the diagnosis of  LRTI. 
Several investigators believe that bronchoscopic sampling is the gold 
standard of care in the diagnosis and management of VAP.[27] 
Protected specimen brush technique: 
   This technique was initially described by Wimberley et al, who using 
an in vitro model of upper airway colonization showed that protection 
25 
 
against contamination was provided by a sampling device protected by a 
double sheathed plugged catheter . The methodology was later standardized 
by Meduri et al.[84] 
Bronchoalveolar Lavage: 
     In this technique the bronchoscope is wedged in the airway of the 
lung to be sampled, and the lavage fluid is introduced and aspirated in a 
standardized manner.[84] BAL samples approximately 10 million alveoli and 
thus represents a larger area than PSB. 
    In patients who are unable to raise sputum spontaneously and in whom 
attempts to induce sputum production are unsuccessful, Fibreoptic 
bronchoscopy is usually the initial procedure. Analysis of bronchoalveolar 
lavage fluid may increase the diagnostic yield of bronchoscopy, especially in 
immunocompromised persons such as patients with AIDS and suspected 
opportunistic infections or patients with suspected non infectious causes of 
chronic pneumonia.[38,95] 
 Non Bronchoscopic distal airways sampling: 
 The endotracheal tube bypasses the proximal airways and allows 
catheters to be passed blindly to sample secretions from distal airways. The 
potential advantages of nonbronchoscopic sampling techniques are less 
invasiveness, less cost, absence of contamination by the bronchoscopic 
channel, and less procedure- related risks to the patient. However, sampling 
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errors can be inherent in a blind technique where the airways are not 
visualized. 
The nonbronchoscopic techniques include : 
1. Plugged telescoping catheter (PTC), 
2.Protected bronchoalveolar mini-lavage (mini-PBAL), and 
3."Blind" PSB. 
       The overall concordance between the bronchoscopic and 
nonbronchoscopic techniques is around 80% which would mean the 
diagnosis could be missed by nonbronchoscopic techniques especially when 
the pneumonia affects the upper lobes of the left lung.[72] Therefore the 
bronchoscopic methods are perhaps the preferred technique whenever the 
option is available and the patient's condition is stable. 
Lung puncture and biopsy: 
     Percutaneous aspiration or needle biopsy may be performed blindly or 
under fluoroscopic guidance, particularly if a localized lesion is present.[117] 
Open lung biopsy is the most invasive procedure and reserved for situations 
in which other measures failed.[77]  
BRONCHOALVEOLAR LAVAGE 
  For more than 20 years, lavage of the bronchial tree through a rigid 
bronchoscope has been used in the management of severe asthma[115] and of 
alveolar proteinosis.[100] Once Myrvik et a1[90] had shown that in rabbits 
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lavage could yield alveolar macrophages, the technique formed the basis of 
the new topic of pulmonary cell biology, now rapidly developing and 
advancing our understanding of a wide variety of pulmonary diseases. The 
methods used for sampling the cells of the pulmonary inflammatory and 
immune systems of man have progressed through lavage via the rigid 
bronchoscope[76] or via a large balloon-tipped catheter wedged into a primary 
or secondary branch of the bronchial tree[54,65] to the present-day 
bronchoalveolar lavage via the fibreoptic bronchoscope.  
   Since its introduction by Professor Shigeto Ikeda in 1964, the use of 
flexible fiberoptic bronchoscopy (FOB) is expanding and it is considered to 
be one the most important breakthrough in diagnostic pulmonology.              
    Bronchoalveolar lavage (BAL) is a specialised technique, described 
by Reynolds and Newball[103] in 1974, which consists instillation of small 
quantity of saline directly into distal airways and recovering the aspirate 
through FOB. This procedure is repeated until a total of 100- 300 ml of 
saline has been instilled. Usually between 40% and 70% of the infused 
volume is recovered, but in patients with destructive lung disease and airflow 
obstruction the proportion is smaller; recovery correlates inversely with the 
severity of the airflow obstruction.[61] 
  Analysis of postmortem lung biopsy has shown that BAL fluid 
cultures to be as useful as PSB cultures. When the results of 11 studies 
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evaluating BAL fluids from a total of 435 ICU patients with suspected VAP 
were pooled, the overall accuracy of this technique was similar to that of 
PSB.[41] Therefore, it is not necessary to perform both BAL and PSB in the 
same patient.[97] BAL is easier to apply, less expensive and does not require 
the specialized brush. It also allows a larger area of the lung to be sampled. 
  A study by Barreiro et al, showed the sensitivity and specificity of 
BAL fluid. Culture of Bronchoalveolar lavage fluid had sensitivity of 87%, 
specificity 91%, positive predictive value of 87% and negative predictive 
value 91%.[7] In a study by Castella et al, sensitivity was 82% and specificity 
was 44%. In another study by Guler et al, the sensitivity was 83% and 
positive predictive value was 50%.[63] 
    BAL is considered as the clinical sample of choice for the 
investigation of Pneumocystis jirovecii.[93] Stains such as Gomori’s 
methenamine silver and Toluidine blue O for cysts and Giemsa for 
trophozoites of Pneumocystis jirovecii, can be performed on smears of 
respiratory specimens[39,64]. The Toluidene blue and Giemsa staining of 
bronchoalveolar lavage fluid is more sensitive and specific for the detection 
of Pneumocystis jirovecii.[78] 
    Analysis of BAL for Acid Fast Bacilli including culture for 
Mycobacterium tuberculosis has significant role to establish the diagnosis 
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when extensive search for AFB in expectorated sputum has repeatedly 
failed, when  sputum expectoration is absent or sputum induction has failed. 
     Caminero et al, concluded that bronchoscopy should be conducted on 
all patients without expectoration and negative sputum smear and that BAL 
performance should be a routine procedure as it is simple and usually 
uncomplicated technique.[24]  Among  various bronchospic specimen BAL is 
considered the best for the diagnosis of tuberculosis.[119] BAL has significant 
sensitivity and specificity in a study by Conde et al, and was useful in the 
diagnosis of PTB in 72% cases.[36] 
Advantages of BAL[15] 
1) This technique is safe and less invasive. 
2) It samples a large area of lung parenchyma. 
3) The recovery of large volume of secretion makes BAL suitable for a   
     series of microscopic analysis that enable early identification of patients  
     with pneumonia. 
4) BAL fluid can be cultured using quantitative technique. 
5) Contamination with upper respiratory flora is prevented. 
6) More useful in isolating Pneumocystis jerovicii from   
      immunocompromised patients. 
7) More sensitive and specific than the sputum sample for the isolation of 
Mycobacterium tuberculosis.  
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     Complications of bronchoalveolar lavage are rare. Transient 
respiratory distress and syncope have been reported,[35] but these are also 
seen in patients undergoing fibreoptic bronchoscopy without 
bronchoalveolar lavage. The most frequent complication is fever, but even 
this is seen in fewer than 3% of patients and rapidly responds to antibiotic 
treatment. 
Procedure:  
As the patient arrives in the bronchoscopy suite (or if the patient is 
already in the hospital), an intravenous catheter (IV) will be started for 
administration of medication and IV fluids. The patient is then connected to 
a monitor for continuous monitoring of the heart rate, blood pressure, and 
oxygen level in the blood. If needed, supplemental oxygen will be supplied 
either through a cannula or a facemask. 
   Patients will be lying on their back with oxygen supplemented through 
the mouth or the nose. Prior to the insertion of the flexible bronchoscope, a 
local anesthesia with topical lidocaine is given in the nose and to the back of 
the throat. The flexible bronchoscope can be introduced either through the 
mouth or the nose. Some patients may require an endotracheal tube to be 
inserted through the mouth, passing the vocal cord, and into the trachea to 
protect and secure the airway. Once the bronchoscope is in the airway, an 
additional topical anesthetic will be sprayed into the airway for local 
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anesthesia to minimize discomfort and coughing spells. A total of 100-300 
ml of 0.9% physiological saline in instilled through the bronchoscope. The 
saline is then aspirated in three aliquots as first, second and third sample for 
microbiological processing. A minimum of 20 ml is necessary for the 
processing. 
Diagnostic techniques: 
a) Microscopic examination of smears 
b) Culture of bacterial and fungal isolates. 
  The sample received is centrifuged at 3000 rpm for 15 mts. The 
supernatant is discarded and the deposit is used for processing.[12] 
A. Microscopic evaluation of smears: 
a) 10% KOH Mount 
   A drop of BAL is placed over a clean glass slide, a drop of 10% 
potassium hydroxide reagent is added over the specimen and a coverslip is 
placed over it taking care to avoid trapping of air bubbles. Proteinaceous 
components, such as host cells are partially digested by the alkali, leaving 
the intact polysaccharide containing fungal cell walls.[74] Tube KOH can be 
used for extended clearing of cells. Clearing can be enhanced by gentle 
heating.  
   In 1998, Sharma et al have reported that KOH preparations 
demonstrated fungus in 100 percent of total culture proven cases.[108] 
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     Bharathi et al in 2006 have concluded that the direct microscopic 
examination of KOH mount is a rapid, reliable and inexpensive diagnostic 
modality, which would facilitate the institution of early antifungal therapy 
before culture results become available.[17] In 1993 Vajpayee et al reported 
that 10% KOH mounts demonstrated fungus in 94.3% of total culture proven 
cases.[118] 
b) Gram’s stain 
     Gram’s staining of bronchoalveolar lavage enables to look for Gram 
positive or Gram negative organisms and helps in early diagnosis. In fungal 
infections, it helps to identify the gram positive yeast cells with hyphae or 
pseudohyphae. For bacteria, Gram’s staining is the most frequently used 
procedure and provide morphological information that can be used in the 
empirical selection of antibiotics for therapy.[13] Results of quantitative 
culture are not available until 24-72 hours after the procedure and potentially 
contribute to the frequent rate of morbidity and mortality.[113] 
    Sole Violan et al  found a correlation between Gram’s staining and 
BAL culture results.[112] In a study by Frederic Duflo et al, the presence of 
micro organism in the initial Gram’s stain is totally correlated with positive 
quantitative cultures. The sensitivity of Gram’s staining was 76.2%, 
specificity 100%, positive predictive value 100% and negative predictive 
value 75.4%.[56] 
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c) Ziehl Neelsen stain  
    Ziehl Neelsen stain (Acid-fast stain) is a useful differential staining 
procedure that specifically stains all members of the genera mycobacteria. 
Being unassociated with the human flora, finding of acid-fast bacilli in 
bronchoalveolar lavage is strongly indicative of an active infection with 
Mycobacterium tuberculosis.  
d) Modified Ziehl Neelsen stain 
     It is called modified Kinyon’s acid fast staining used for the 
identification of other Acid fast organisms like Nocardia, Cryptosporidia 
etc. The concentration of sulphuric acid used is 1%. The filaments of 
Nocardia spp. are partially acid fast when stained by modified acid fast 
technique. 
e) Toluidene blue O stain  
      Toluidene blue O stain is used for staining the cysts of Pneumocystis 
jirovecii. It is especially useful in immunocompromised patients like patients 
with HIV infection. Toluidene blue staining of bronchoalveolar lavage fluid 
has increased sensitivity and specificity for the identification of cysts of 
Pneumocystis jirovecii.[58] 
f) Giemsa stain 
      Giemsa staining has been routinely used for the detection of 
trophozoites and intracystic bodies in smears of bronchoalveolar lavage fluid 
34 
 
(BAL) from patients with Pneumocystis jirovecii pneumonia. Sulphation of 
smears before staining with Giemsa allows cysts to be visualised, thus 
enabling a single stain to be used to show all the stages of Pneumocystis 
jirovecii in BAL or sputum, which is particularly useful, considering the 
increase in the prevalence of Pneumocystis jirovecii pneumonia in 
conjunction with the spread of AIDS.[120] 
Bacterial culture: 
  Semi-quantitative loop method is used for culturing bacteria. A 
calibrated loop is used to plate out 0.01ml of fluid. The deposit of 
centrifuged sample is spreaded on MacConkey agar, Chocolate agar and 
Blood agar plates by standard method and incubated at 37ºC for 24 hrs. 
Sample with colony count of ≥ 104 cfu/ml is considered to have significant 
growth for Bronchoalveolar lavage fluid.[18] 
 Fungal culture: 
   The sample is centrifuged and the deposit is inoculated onto two 
Sabourauds Dextrose Agar slants and incubated at 25º and 37ºC. 
Interpretation of growth: 
Bacterial: 
  The specific identification of bacterial pathogens was based on the 
microscopic morphology, staining characteristics and biochemical properties 
using standard laboratory criteria.[1] 
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Fungal:  
 Fungal isolates were identified by studying the colony morphology, 
colony colour, production and arrangement of conidia in preparations stained 
by Lactophenol cotton blue stain.[49] When identification is difficult due to 
inadequate sporulation, Riddle’s slide culture technique can be employed.[47] 
Antimicrobial Susceptibility Testing: 
   As resistance patterns to commonly used antibiotics and antifungals 
for the treatment of lower respiratory tract infections continue to shift, 
sensitivity testing play an important role in appropriate management of 
individual cases based on susceptibility characteristics and for community 
surveillance. 
Antibacterial Susceptibility: 
  Antibacterial sensitivity testing was performed by the Kirby-Bauer 
disc diffusion technique, using 0.5 McFarland’s turbidity as the standard 
inoculum density on Mueller Hinton agar plates. Commercially available  
Hi-Media antibiotic discs were used. 
Antifungal Susceptibility: 
  The recent increased incidence of fungal infections and the growing 
number of new antifungal agents have multiplied the demand and interest 
for in vitro antifungal susceptibility testing.[1] 
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Antifungal susceptibility testing can be performed by[88] 
Agar based methods: 
1. Agar dilution method 
2. Disc diffusion method 
3. E-test method 
Broth based methods: 
1. Broth macrodilution method 
2. Broth microdilution method 
3. Calorimetric methods. 
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MATERIALS AND METHODS 
PERIOD OF STUDY 
  This is a cross sectional study undertaken over a period of one year 
from May 2009 to May 2010. 
PLACE OF STUDY 
    This study was carried out at the Institute of Microbiology, Madras 
Medical College, Chennai and Institute of Thoracic Medicine, Government 
General Hospital, Chennai. 
STUDY MATERIAL 
  All bronchoalveolar lavage samples from patients with lower 
respiratory tract infections collected by fibreoptic bronchoscopy in the 
Institute of Thoracic Medicine, Government General Hospital, Chennai 
ETHICAL CONSIDERATIONS 
 Written consent to participate in the study was obtained from the 
patients or their guardians after providing full explanation of the study. This 
study was reviewed and approved by Institutional Ethical Committee, 
Madras Medical College & Government General Hospital, Chennai 3. All 
data were handled confidentially and anonymously. 
STATISTICAL ANALYSIS 
     Statistical analyses were carried out using Statistical Package for 
Social Sciences (SPSS) and Epi-Info softwares by a statistician. The 
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proportional data of this cross sectional study were tested using Pearson’s 
Chi Square analysis test and Binomial proportion test. 
SPECIMEN COLLECTION 
   Fibreoptic bronchoscopy is inserted transnasally or per orally, 
minimum 60 ml of 0.9% physiological normal saline is instilled and then 
aspirated. A minimum of 20 ml should be collected for processing in the 
microbiology laboratory. 
SPECIMEN PROCESSING 
  Three sets of samples were taken, centrifuged at 3000rpm for 15 mts 
and the deposit was processed as follows 
1. First set of sample was used for microscopic examination. 
       a) 10% Potassium hydroxide (KOH) mount preparation,  
       b) Gram’s stain procedure 
       c) Ziehl-Neelsen staining  
       d) Modified Ziehl-Neelsen staining,  
       e) Toluidine blue O staining 
        f) Giemsa staining.  
2. Second set of sample was inoculated onto solid media like blood agar,          
    chocolate agar and MacConkey agar. 
3. Third set of sample was inoculated onto two slants of Sabouraud’s 
dextrose agar (SDA) devoid of antibiotics and cycloheximide. 
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a) Microscopic Examination: 
  a) 10% KOH mount preparation was examined for the presence of 
septate or aseptate hyphal elements, conidial forms or yeast forms. 
    b)Gram positive or Gram negative organisms or yeast cells were 
looked for in Gram’s stain preparation. 
    c) Fixed smear was stained by acid fast staining and looked for any 
acid fast bacilli. 
       d) Modified acid fast staining was done for identifying Nocardia spp. 
     e) Smear was stained with Toluidene blue and Giemsa stains and 
examined for the presence of trophozoites and cysts of Pneumocystis 
jirovecii. 
b) Culture: 
    The centrifuged deposit of bronchoalveolar lavage was inoculated on 
MacConkey agar, blood agar and chocolate agar plates and incubated at 
37ºC for 24 hrs. The two inoculated SDA slants were incubated at 25ºC and 
37ºC for up to 4 weeks.[101] 
Interpretation of Bacterial culture: 
    Bacterial culture plates were observed for growth at 24 hours. If there 
are < 10 colonies on the plate, that equates < 103 cfu/ml, between 10-100 
colonies indicate 103-104 cfu/ml and 100-1000 colonies indicate 104-105 
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cfu/ml. The diagnostic threshold for bronchoalveolar lavage is 
≥104cfu/ml.[12] 
    Bacterial isolates were identified by means of Gram’s staining, 
motility and biochemical reactions by standard microbiological techniques as 
recommended by Clinical and Laboratory Standards Institute (CLSI). 
    All bacterial isolates were preserved in 0.2 – 0.5 % semisolid Nutrient 
agar slopes at 4 – 5º C in refrigerator with periodic subculture every 2 
months.[104] 
Interpretation of Fungal culture: 
      Two SDA slants were inoculated and incubated at 25ºC and 37ºC for 
minimum of 4 weeks before reporting as negative. These slants were 
inspected daily during the first week and twice weekly during the next three 
weeks for growth.[70] Growth on the slants with presence of hyphal elements 
in 10% KOH preparation was regarded as significant fungal growth. 
     Identification of filamentous fungi was done by preparing Lacto 
Phenol Cotton Blue mount and studying the morphology of hyphae and 
conidial arrangement. In difficult, ambiguous cases where sporulation was 
inadequate, Riddle’s slide culture technique was performed.[47] 
Lactophenol Cotton Blue stain:[69] 
     Place a drop of Lactophenol Cotton Blue Stain in the center of a clean 
slide. Remove a fragment of the fungus colony 2-3mm from the colony edge 
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using an inoculating or teasing needle. Place the fragment in the drop of stain 
and tease gently. Apply a coverslip. Do not push down or tap the cover slip 
as this may dislodge the conidia from the conidiophores. Examine the 
preparation under low and high, dry magnification for the presence of 
characteristic mycelia and fruiting structures.  
Riddle’s slide culture technique:[47] 
    This was used to study the undisturbed morphological details of fungi, 
particularly the relationship between reproductive structures and mycelium. 
Procedure:  
1. A round piece of filter paper was placed on the bottom of a sterile Petri 
dish. A pair of thin glass rods was placed on top of the filter paper to 
serve as supports for a 3 inch × 1 inch glass microscopic slide. 
2. A small 1cm block of SDA previously poured into a Petridish was placed 
on the surface of the microscopic slide. The block was cut using a sterile 
scalpel. 
3. A small portion of the fungal colony to be studied was inoculated onto 
three or four places in the margins of the agar block using a straight 
inoculating wire. 
4. A coverslip was gently heated by passing it quickly through the flame of 
a Bunsen burner and immediately placed directly on the surface of the 
inoculated agar block. 
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5. A small amount of water was placed into the bottom of the petri dish to 
saturate the filter paper. 
6. The Petridish was incubated at 30ºC for 3-5 days. 
7. When a growth visually appeared to mature, the coverslip was gently 
lifted from the surface of the agar with a pair of forceps taking care not to 
disrupt the mycelium adhering to the bottom of the coverslip. 
8. The coverslip was placed on a small drop of LPCB on a second glass 
slide. Likewise, the mycelium adhering to the surface of the original glass 
slide after the block was removed also was stained with LPCB and a fresh 
coverslip was overlaid. 
9. The characteristic shape and arrangement of spores was observed 
microscopically. 
    In case of yeasts, identification and speciation was done by Gram’s 
stain morphology, germ tube test, morphology on corn meal agar, and 
biochemical tests by standard microbiological techniques as recommended 
by CLSI. 
Gram’s stain 
       Gram positive oval budding yeasts cells with presence or absence 
of pseudohyphae. 
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Germ Tube test 
    A loopful of creamy white yeast like colony from SDA was taken and 
it was inoculated into 0.5ml of mammalian serum. It was incubated at 37ºC 
for one and a half to 2 hours. After incubation period, a loop full of this 
serum suspension was placed on a clean glass slide and covered with cover 
slip and focused under high power objective to see the characteristic germ 
tube formation . 
Chromagar 
      A single colony from Sabourauds dextrose agar was taken and it was 
streaked on chromagar and incubated at 37°C for 48 hrs. After incubation 
period, the plates were observed for characteristic coloured colonies of 
candida. 
Cornmeal agar 
   A single colony from Sabouraud’s dextrose agar was inoculated on to 
a plate of cornmeal agar containing 1%Tween 80 and trypan blue. Three 
parallel steaks were made about half an inch apart at a 45º angle to the 
culture medium. A sterile coverslip was placed over it and incubated at 30ºC 
for 48 hrs. After incubation the areas where the cuts into the agar were made 
were examined for the presence of blastoconidia, arthroconidia, 
pseudohyphae, hyphae or chlamydoconidia.[5] 
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Carbohydrate fermentation test[5] 
     A saline suspension of the yeast colonies was prepared. About 0.2ml 
of this suspension was inoculated on to the carbohydrate fermentation broth 
that contain Durham’s tube and different sugars at a concentration of 2%. 
The different sugars used were glucose, lactose, sucrose, maltose 
respectively. The tubes were incubated at room temperature for 7-10 days. 
After incubation period, the tubes were observed for acid and gas 
production. 
Carbohydrate assimilation test[5]  
   Organisms from SDA were inoculated onto carbohydrate free 
medium either in nutrient agar or blood agar. A suspension of the yeast in 
saline or distilled water to a density equivalent to a McFarland No.4 standard 
was prepared. The saline suspension was swabbed on sterile 
yeast nitrogen base agar plate.  
   The different carbohydrate disc used include glucose, lactose, 
sucrose, maltose, galactose, trehalose , raffinose. The disc were placed on to 
the surface of the agar approximately 30mm apart from each other. The 
plates were incubated at 30ºC for 24 to 48hrs. 
  After incubation, the plates were observed for the presence of a colour 
change around the carbohydrate containing discs or the presence of growth 
surrounding them. All fungal growths were preserved by suspending a small 
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inoculum of spores or conidia in sterile distilled water and kept in sterile 
cryo vials at room temperature.[70]* 
SENSITIVITY TESTING OF ISOLATES 
ANTIBACTERIAL SUSCEPTIBILITY TESTS: 
   Bacterial isolates were subjected to antibiotic sensitivity by the Kirby-
Bauer’s Disc Diffusion technique on Mueller Hinton agar plates as 
recommended by CLSI. Peptone water culture of the bacterial isolates 
corresponding to 0.5 McFarland’s turbidity was used as inoculum. The entire 
dried agar surface was evenly streaked in three different directions with a 
sterile cotton swab dipped into the inoculum.[104] 
   Commercial Hi-Media Antibiotic discs were used. Maximum six 
antibiotic discs were used for each 9cm diameter petridish.. These plates 
were incubated at 37ºC for 16–18 hours in ambient air. The diameters of 
zones of inhibition were interpreted according to CLSI standards[33] for each 
organism. Media and discs were tested for quality control using standard 
strains. 
The following standard strains were used 
   Staphylococcus aureus-ATCC 25 
Escherichia coli-ATCC 25922 
   Pseudomonas aeruginosa-ATCC 27853 
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The antibiotic discs used for gram negative bacilli were: 
Antimicrobial agent Inhibition zone in mm 
Resistant Intermediate Sensitive 
Amikacin 30µg 14 15-16 17 
Amoxicillin/clavulanic acid 20/10µg 13 14-17 18 
Ceftazidime 30 µg 14 15-17 18 
Cefotaxime 30 µg 14 15-22 23 
Ciprofloxacin 5 µg 15 16-20 21 
Cotrimoxazole 1.25/23.75 µg 10 11-15 16 
Gentamicin 10 µg 12 13-14 15 
Imipenem 10 µg 13 14-15 16 
 
The antibiotic discs used for Gram Positive Cocci were: 
Antimicrobial agent Inhibition zone in mm 
Resistant Intermediate Sensitive 
Amikacin 30 µg 14 15-16 17 
Amoxicillin/clavulanic acid 20/10 µg 13 14-17 18 
Ampicillin 10 µg 28 - 29 
Ceftriaxone 30 µg 13 14-20 21 
Cefotaxime 30 µg 14 15-22 23 
Ciprofloxacin 5 µg 15 16-20 21 
Cotrimoxazole 1.25/23.75 µg 10 11-15 16 
Erythromycin 15µg 13 14-22 23 
Oxacillin 1µg 10 11-12 13 
Vancomycin 30 µg - - 15 
                                                                                                         CLSI 2010 
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Minimum inhibitory concentration (MIC) for detecting 
Methicillin resistance:[34] 
     MIC was performed for Oxacillin by broth microdilution method for 
Staphylococcus aureus isolates to detect Methicillin Resistant 
Staphylococus aureus (MRSA). 
      The test was performed using Mueller Hinton broth with 2% Sodium 
chloride in a microtitre plate. The bacterial suspension adjusted to 0.5 
McFarlands turbidity was further diluted ten times to give a final 
concentration of 5 × 105 CFU/ ml in each well. 
     The range of concentration of Oxacillin used was 0.125µg/ml – 
32µg/ml. After inoculation, the microtitre plates were incubated in ambient ir 
at 35ºC for 24 hours. The drug controls and the growth controls were 
included in each test. 
Interpretation 
    The MIC value is the lowest concentration of Oxacillin that 
completely inhibits visible growth of the test organism. Growth in the wells 
with Oxacillin dilutions should be compared with the growth in the control 
wells for determining the end point. 
Screening of ESBL producing strains: 
     Clinical and Laboratory Standards Institute (CLSI) has developed 
screening test for identifying the ESBL producing strains. 
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     According to CLSI guidelines, strains showing zones of inhibition  ≥ 
27mm for cefotaxime were selected for conformational tests of ESBL. 
Klebsiella pneumoniae ATCC 700603 ESBL positive strain was used as 
control along with Escherichia coli ATCC 25922 as negative control. 
ESBL confirmatory test: 
1. Double Disc Synergy test (DDST)[71] 
   The isolated colonies were inoculated in peptone water at 37°C for 2-6 
hrs. The turbidity was adjusted to 0.5 Mc Farland’s standard and lawn 
culture was made on Muller Hinton agar using sterile swab. Augmentin disc 
(20/10 µg) was placed in the centre of plate. Both side of Augmentin disc, a 
disc of cefotaxime (30 µg) and cetazidime (30 µg) were placed with centre to 
centre distance of 15mm to centrally placed disc. The plate was incubated at 
37°C overnight, ESBL production was interpreted as the 3rd generation 
Cephalosporin disc inhibition was increased towards the Augmentin disc or 
if neither discs were inhibitory alone but bacterial growth was inhibited 
where the two antibiotics were diffused together. 
2. Phenotypic Confirmatory Disc Diffusion Test (PCDDT) for ESBL[71] 
      Antibacterial susceptibility testing was done on Muller Hinton Agar 
with 0.5 McFarlands standards of the organism. Lawn Culture of the 
organism was made and 3rd generation Cephalosporins Cefotaxime (30µg) 
disc and Cefotaxime with Clavulinic acid (30 µg + 10 µg ) disc was placed 
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with 25mm apart. An increase of ≥ 5mm in zone of inhibition for 
Cefotaxime with Clavulinic acid compared to Cefotaxime was confirmed as 
ESBL producers. 
ANTIFUNGAL SUSCEPTIBILITY TESTS: 
   The antifungal susceptibility tests was done by two methods 
1) DISC DIFFUSION METHOD 
2) BROTH MICRODILUTION METHOD 
Disc diffusion method 
       This method was used for the Candida species. 
Inoculum preparation: 
     The inoculum suspension was prepared by picking five colonies, each 
of atleast 1mm in diametrer, from 24 hour old culture of Candida spp. and 
suspending the material in 5ml of sterile saline. The suspension was then 
adjusted spectrophotometrically at 530nm to match the transmittance 
produced by 0.5 McFarland’s barium sulphate standard. This procedure 
produces an inoculums size 1× 106 to 5× 106cfu/ml. The following standard 
strain was tested each time to ensure quality control : Candida albicans 
ATCC 90028 
Procedure 
It was performed on Muller Hinton agar plate supplemented with 
2% glucose and 0.5 µg/ml methylene blue.[31] 
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       Antifungal susceptibility testing was carried out following the M44-A, 
National Committee for Clinical Laboratory Standards (NCCLS) guidelines, 
using Amphotericin B, Fluconazole and Itraconazole antifungal discs. 
     The entire dried agar surface was evenly streaked in three different 
directions with a sterile cotton swab dipped into the inoculum suspension. 
The plate was allowed to dry for 20 minutes. Using a pair of flame sterilized 
forceps the antifungal discs were applied onto the surface of the inoculated 
plate. The plates were incubated at 35ºC for 48 hours. The plates were read 
at 24hrs and 48hrs.[51] 
     The following commercial Hi-Media antifungal discs were used 
Amphotericin B 100 units 
Itraconazole 10µg 
Fluconazole 10µg 
Interpretation 
    Zone diameters were measured to the nearest whole millimeter at the 
point where there was prominent reduction of growth.[89] 
Broth microdilution method  
     This method was used for filamentous fungi 
    The Clinical and Laboratory Standards Institute (CLSI) subcommittee 
on Antifungal Susceptibility Tests has developed a reproducible procedure 
for antifungal susceptibility testing of filamentous fungi by a broth 
51 
 
microdilution format the M-38A document. Recently, an agar diffusion 
method has been developed for testing filamentous fungi by disc diffusion 
methodology. 
Inoculum preparation 
    Mould stock inoculum suspensions were prepared from fresh mature 
(7 day old) cultures grown on Potato dextrose agar following CLSI 
guidelines. A conidial suspension was prepared by flooding each slant with 
sterile distilled water. To reduce the hydrophobicity of the conidia and to aid 
with the formation of uniform conidial suspension of Aspergillus spp., 
Tween 80 was added to the sterile distilled water. 
   The resulting suspension was permitted to stand for 5 minutes to allow 
large particles to settle down. The suspension was then adjusted 
spectrophotometrically at 530 nm to the optical density range of 0.09-0.11 
for Aspergillus spp. to get an inoculum size of 1.6 × 106 CFU/ ml.[89] 
Procedure 
    This was done as per CLSI document M 27-A 2 for Yeasts, CLSI, 
Pennsylvania, USA 2002.16 
       The test was performed in a 96 well microtitre plate using standard 
RPMI1640 medium. MIC range of Amphotericin B : 0.03 – 16 µg/ml 
      The following standard strains were tested each time to ensure quality 
control: 
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Aspergillus flavus ATCC 204304 
Aspergillus fumigatus ATCC 204305 
      Due to the lack of defined breakpoints for Amphotericin B, isolates 
showing an MIC of 1.0 µg/ ml were taken as susceptible and those with MIC 
>1 µg /ml were considered as resistant.[102] The MIC for Amphotericin B was 
defined as the lowest concentration in which an optically clear well was 
observed.[32] 
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RESULTS 
TABLE: 1 
SEX DISTRIBUTION OF CASES (n = 100) 
 
 
                                                                                   
                                                                             P < 0.05 
67% of the cases with lower respiratory tract involvement were males and 
88% were females. This is statistically significant. 
TABLE: 2 
AGE DISTRIBUTION OF CASES (n = 100) 
Age group No. of cases 
< 20 years 7 (7%) 
21 – 40 years 23 (23%) 
41 – 60 years 52 (52%) 
> 61 years 18 (18%) 
                                                                                 P < 0.001 
52% of cases were in the 41-60 years age group and 23% of cases in the 21-
40 years of age. This is statistically significant. 
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TABLE: 3 
CASE DISTRIBUTION 
Pneumonia  33 (33%) 
Lung abscess 16 (16%) 
Lung tumours 15 (15%) 
Pulmonary tuberculosis 12 (12%) 
Transplant recipients with pulmonary infiltration  6 (6%) 
Hydropneumothorax  4 (4%) 
Chronic bronchitis 4 (4%) 
Renal failure with LRTI 2 (2%) 
Bronchoalveolar carcinoma 2 (2%) 
Allergic broncho pulmonary aspergillosis 2 (2%) 
Aspergilloma  1 (1%) 
Carcinoma parotid with secondaries neck 1 (1%) 
Mediastinal fibrosis 1 (1%) 
Sarcoidosis  1 (1%) 
               
   Pneumonia (33%) was the most common LRTI evaluated by 
bronchoalveolar lavage sampling, followed by lung abscess (16%) and 
tumours (15%). 
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TABLE: 4 
CULTURE POSITIVITY OF BRONCHOALVEOLAR LAVAGE 
SAMPLES (n=100) 
Total no. of 
samples 
No. of culture 
positive samples
Percentage of 
positivity 
Total no. of 
Bacteria & 
Fungi isolated 
100 60 60 69 
 
Out of the total 100 samples, 69 aetiological agents were isolated from 
60 samples with culture positivity of 60% 
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TABLE: 5 
ORGANISMS ISOLATED FROM BRONCHOALVEOLAR LAVAGE 
(n=69) 
Gram positive cocci 7 10.14% 
Gram negative bacilli 47 68.1% 
Fungal isolates 15 21.7% 
                                                                                 P < 0.0001 
Majority of the isolated agents were gram negative bacilli (68%) followed by 
fungal isolates (21.7%). This is statistically significant. 
 
TABLE: 6 
BACTERIAL ISOLATES IN BRONCHOALVEOLAR LAVAGE 
(n=54) 
 
 
   Klebsiella spp. were the most common bacterial isolates in broncho 
alveolar lavage accounting for 33.3% of infection followed by Pseudomonas 
aeruginosa and Acinetobacter spp. (16.7%). 
Klebsiella pneumonia 12 22.2% 
Klebsiella oxytoca 6 11.1% 
Pseudomonas aeruginosa 9 16.7% 
Acinetobacter spp. 9 16.7% 
Staphylococcus aureus 6 11.1% 
Escherichia coli 5 9.3% 
Proteus vulgaris 4 7.4% 
Streptococcus pneumonia 1 1.9% 
Proteus mirabilis 1 1.9% 
Citrobacter koseri 1 1.9% 
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TABLE: 7 
FUNGAL ISOLATES IN BRONCHOALVEOLAR LAVAGE (n=15) 
 
 
    Among the fungal isolates, Candida spp. were the most common 
isolates (73.3%), followed by Aspergillus spp. (20%). 
 
TABLE: 8 
NATURE OF THE ISOLATES (n=60) 
Monomicrobial  
             Bacterial  
             Fungal 
 
39 (65%) 
12 (20%) 
Polymicrobial  
              Bacterial with bacterial  
              Bacterial with fungal 
 
6 (10%) 
3 (5%) 
 
   Of the culture positive samples, 15% showed mixed infections. 
Among them 10% was bacterial with bacterial isolate and 5% bacterial with 
fungal. Polymicrobial infections were more common in Pneumonia and lung 
abscess.  
Candida spp. 11 73.3% 
Aspergillus flavus 2 13.3% 
Aspergillus fumigatus 1 6.7% 
Syncephalastrum spp. 1 6.7% 
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TABLE: 9 
SMEAR POSITIVITY FOR ACID FAST BACILLI BY ZIEHL 
NEELSEN METHOD 
Total No. of samples 100 
Positive by AFB stain 11 (11%) 
Negative by AFB stain 89 (89%) 
 
Acid Fast Bacilli were found in 11% of samples. 
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TABLE: 10 
ANTIBACTERIAL SENSITIVITY PATTERN OF GRAM-POSITIVE ORGANISMS BY KIRBY BAUER’S 
METHOD (n=7) 
Organism Penicillin Ampicillin Oxacillin Erythromycin Cotrimoxazole Cefotaxime Amikacin Cipro 
floxacin 
Vanco 
mycin 
Strep. 
pneumoniae 
(n=1) 
 
Staph.aureus 
(n=6)  
 
MSSA(2) 
 
MRSA(4) 
 
1(100%) 
 
 
 
 
 
2(100%) 
 
0 
 
1(100%) 
 
 
 
 
 
2(100%) 
 
0 
 
1(100%) 
 
 
 
 
 
2(100%) 
 
0
 
1(100%) 
 
 
 
 
 
2(100%) 
 
3(75%)
 
1(100%) 
 
 
 
 
 
2(100%) 
 
3(75%)
 
1(100%) 
 
 
 
 
 
2(100%) 
 
0
 
1(100%) 
 
 
 
 
 
2(100%) 
 
4(100%)
 
1(100%) 
 
 
 
 
 
2(100%) 
 
3(75%)
 
1(100%) 
 
 
 
 
 
2(100%) 
 
4(100%) 
MSSA – Methicillin Sensitive Staphylococcus Aureus 
MRSA – Methicillin Resistant Staphylococcus Aureus 
         Among the Staphylococcus aureus isolates, 66.7% was methicillin resistant. All the Staphylococcus aureus were 
sensitive to vancomycin. 
RESISTANCE PATTERN IN STAPHYLOCOCCUS AUREUS 
  
  
0.00% 1
MSSA
MRSA
0.00% 20.00%
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TABLE:11 
ANTIBACTERIAL SENSITIVITY PATTERN OF GRAM-NEGATIVE ORGANISMS BY KIRBY BAUER’S 
METHOD  (N=47) 
Organism Ampicillin Cotrimoxazole Cefotaxime Amikacin Ceftazidime Gentamicin Ciprofloxacin Imipenem 
Klebsiella 
pneumoniae 
(n=12) 
3(25%) 6(50%) 7(58.3%) 10(83.3%) 8(66.7%) 9(75%) 11(91.6%) 12(100%) 
Klebsiella oxytoca 
(n=6)  3(50%) 2(33.3%) 3(50%) 5(83.3%) 4(66.7%) 3(50%) 4(66.7%) 6(100%) 
Pseudomonas 
aeruginosa (n=9) 2(22.2%) 3(33.3%) 5(55.6%) 8(88.9%) 7(77.8%) 6(66.7%) 8(88.9%) 9(100%) 
Acinetobacter spp. 
(n=9) 6(66.7%) 8(88.9%) 6(66.7%) 9(100%) 8(88.9%) 8(88.9%) 8(88.9%) 9(100%) 
Escherichia coli 
(n=5) 3(60%) 4(80%) 4(80%) 5(100%) 5(100%) 5(100%) 3(60%) 5(100%) 
Proteus vulgaris 
(n=6) 4(66.7%) 5(83.3%) 5(83.3%) 6(100%) 5(83.3%) 4(66.7%) 4(66.7%) 6(100%) 
Proteus mirabilis 
(n=1) 1(100%) 0 1(100%) 1(100%) 1(100%) 0 0 1(100%) 
Citrobacter koseri 
(n=1) 1(100%) 1(100%) 1(100%) 1(100%) 1(100%) 0 0 1(100%) 
 
All the Gram Negative Isolates were sensitive to Imipenem. 
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TABLE: 12 
DISTRIBUTION OF RESULTS OF SCREENING TEST FOR ESBL 
(Cefotaxime: zone of inhibition > 27 mm – sensitive, < 27 mm – resistant) 
 
Organism 
Sensitive to 3rd gen 
Cephalosporins 
Resistant to 3rd gen 
Cephalosporins 
No. of 
isolates 
Percentage No. of 
isolates 
Percentage
Klebsiella 
pneumoniae (n=12) 
7 58% 5 42% 
Klebsiella oxytoca 
(n=6) 
3 50% 3 50% 
Escherichia coli 
(n=5) 
4 80% 1 20% 
Proteus vulgaris 
(n=4) 
3 75% 1 25% 
 
Eight isolates of Klebsiella spp., one of Escherichia coli and one of 
Proteus vulgaris were resistant to third generation cephalosporins. 
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TABLE: 13 
COMPARISON OF SCREENING TESTS WITH DDST AND PCDDT 
 
Organism 
No. of 
screened 
isolates for 
ESBL 
 
 
DDST 
 
PCDDT 
Klebsiella pneumoniae 
(n=12) 
5 (42%) 4 (33.3%) 4 (33.3%) 
Klebsiella oxytoca (n=6) 3 (50%) 2 (33.3%) 2 (33.3%) 
Escherichia coli (n=5) 1 (20%) 1 (20%) 1 (20%) 
Proteus vulgaris (n=4) 1 (25%) 1 (25%) 1 (25%) 
 
10 isolates were selected and subjected for confirmatory tests. 8 isolates 
were confirmed as ESBL Producers by PCDDT. 
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TABLE: 14 
ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA SPP. BY DISC 
DIFFUSION METHOD (n=11) 
Isolate Amphotericin B Fluconazole Itraconazole 
Sensitive Resistant sensitive resistant sensitive Resistant
Candida 
albicans 
(n=8) 
8(100%) - 8(100%) - 8(100%) - 
Candida 
tropicalis 
(n=3) 
3(100%) - 1(33.3%) 2(66.7%) 3(100%) - 
 
All the isolates of Candida albicans and Candida tropicalis were 
sensitive to Amphotericin B and Itraconazole. 2 isolates (66.7%) of Candida 
tropicalis showed resistance to Fluconazole. 
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TABLE: 15 
ANTIFUNGAL SUSCEPTIBILITY OF ASPERGILLUS BY 
MICROBROTH DILUTION METHOD 
 
Isolates 
Amphotericin B 
Sensitive 
MIC ≤ 1 µg/ml 
Resistant 
MIC ≥ 1 µg/ml 
Aspergillus fumigatus 
(n=1) 
1(100%) 0 
Aspergillus flavus (n=2) 2(100%) 0 
 
All the Aspergillus spp. were susceptible to Amphotericin B. 
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TABLE: 16 
SCREENING BY DIRECT GRAM’S STAIN 
Gram’s Stain 
Bacterial Culture 
Total 
Positive Negative
Positive  43 2 45 
Negative  11 44 55 
Total  54 46 100 
 
Gram’s staining showed sensitivity of 79.6% and specificity of 95.6%. 
 
TABLE: 17 
SCREENING BY 10% KOH MOUNT FOR FUNGAL ELEMENTS 
10% KOH 
Mount  
Fungal Culture 
Total 
Positive Negative
Positive  14 - 14 
Negative  1 85 56 
Total  15 85 100 
 
10% KOH mount screened for fungal elements showed sensitivity of  
93.3%. 
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FIBRE OPTIC BRONCHOSCOPE 
 
 
DIRECT GRAM STAIN 
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ACID FAST BACILLI 
 
 
 
GRAM NEGATIVE BACILLI 
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GROWTH OF KLEBSIELLA PNEUMONIAE IN MACCONKEY 
AGAR 
 
BIOCHEMICAL REACTION OF KLEBSIELLA PNEUMONIAE 
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GROWTH OF PSEUDOMONAS SPP IN MACCONKEY AGAR 
 
 
DISTORTION OF ZONE OF INHIBITION FOR DETECTION OF 
ESBL PRODUCERS 
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SPECIATION OF CANDIDA SPP USING CHROM AGAR 
 
 
 
ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA SPP BY DISC 
DIFFUSION METHOD 
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ANTIFUNGAL SUSCEPTIBILITY TESTING FOR AMPHOTERICIN 
B USING MICROBROTH DILUTION METHOD 
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DISCUSSION 
        Lower respiratory tract infections are the major cause of morbidity and 
mortality worldwide. They remain the leading cause of deaths among the 
infectious diseases.[105] Hence earlier diagnosis and treatment is essential. 
      The etiological agents of lower respiratory tract infection are not 
determined in 50% of patients despite extensive diagnostic testing .[6] 
      Most of the specimens used for the diagnosis of pulmonary infections 
have drawbacks like contamination with oropharyngeal flora or invasive 
nature of some of the procedures. 
       Bronchoalveolar lavage is a deeper sampling technique and is now 
reported to have value in diagnosing pulmonary infections.[25] 
Bronchoalveolar lavage is especially suitable for detecting cysts of 
Pneumocystis jirovecii, fungal elements and Mycobacteria[23] particularly in 
immuncompromised patients. 
    Various workers stressed upon the utility of bronchoalveolar lavage in 
the diagnosis and monitoring of lung diseases.[18] This study was aimed to 
evaluate the common aerobic bacterial and fungal isolates in bronchoalveolar 
lavage and to analyse the antimicrobial sensitivity pattern of the isolated 
organisms. 
        In this study the occurrence of lower respiratory tract pathology was 
found to be more common in males (67%) than females (33%). P < 0.05 
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significant. [Table:1] This is similar to the study by Karen C.Caroll et al 
(2002), which revealed 62% cases in males.[75] Similar findings were 
observed in the study by Reimer et al (1998) and Leatherman et al with 65% 
and 70% of predominance in males respectively.[101,81] 
        The distribution of cases was found to be more common in the age 
group of 41-60 years (52%) in this study. P < 0.001 significant. [Table:2] 
This observation correlates with the study by Karen et al (2002), who 
reported higher prevalence among patients more than 40 years of age.[75] The 
study by Grayston et al (1994), also showed a higher prevalence in 41-60 
years age group.[59] 
        The most common LRTI that required bronchoalveolar lavage analysis 
in this study was found to be pneumonia (33%) followed by lung abscess 
and tumours  [Table:3]. This was similar to the study by Reimer et al (1998) 
and Kahn et al, which showed higher prevalence of pneumonia among the 
lower respiratory infections.[101,73] 
         According to this study, the etiological agents were isolated in 60 
Bronchoalveolar lavage samples (60%). Of these 60 positive samples, 39 
(65%) had single bacterial isolate, 12 (20%) had single fungal  isolate and 9 
(15%) had mixed infections. Of the mixed infections, 10% of the sample 
showed more than one bacterial isolate and 5% showed bacterial with fungal 
growth. [Table:8] 
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          These observations were similar to the study be G.C. Bhatia et al 
(2006), which revealed pure bacterial growth in 61% and pure fungal growth 
in 16.7% in bronchoalveolar lavage.[18] This result also correlates well with 
the study by Karen et al (2002), in which the mixed infections were about 
18%. 
           Among the 69 isolates, 54 isolates (78.3%) were bacterial and 15 
isolates (21.7%) were fungal. P < 0.05 significant. 
         In the present study, aerobic gram negative bacilli were found in 
68.1% of cases. P < 0.0001 significant. [Table:5]. The predominant isolate 
was Klebsiella spp.(Klebsiella pneumoniae and Klebsiella oxytoca) (33.3%) 
followed by Pseudomonas aeruginosa (16.7%) and Acinetobacter spp. 
(16.7%). Other gram negative bacilli were Escherichia coli (9.3%), Proteus 
spp. (9.3%) and one isolate of Citrobacter koseri(1.9%). Gram positive cocci 
were found in 12.9% of cases. Staphylococcus aureus was the predominant 
isolate [Table:6] 
         A study conducted by Crystal et al (1996) showed the predominant 
isolates in bronchoalveolar lavage were gram negative bacilli particularly in 
hospital acquired infections.[37] Among those, Klebsiella pneumoniae was 
found in 30%. These observations were similar to the study by Bhatia et al 
(2006), where the percentage of Klebsiella spp. was 32%.[18] 
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         The next common isolates following Klebsiella spp. were 
Pseudomonas aeruginosa (16.7%) and Acinetobacter spp. (16.7%). This 
correlates well with the study by Frederick et al (1998).[56] 
         In this study among the culture positive cases, 22% were positive for 
fungal isolates. Among the fungal isolates, 73.3% was Candida spp. and 
20% Aspergillus spp ( Aspergillus flavus and Aspergillus fumigatus). with 
Candida albicans being the most common isolate [Table:7] 
          This is similar to the study by Bjermer et al (1992), where the fungal 
isolates in bronchoalveolar lavage was 20% and Candida albicans was the 
most common isolate.[19] This also correlates with the study by Bhatia et al 
(2006), in which Candida albicans was the most common fungal isolate 
forming 12% of the total culture positive samples and 83.3% of the total 
fungal isolates.[18] 
          In the present study, all the samples of Bronchoalveolar lavage fluids 
were screened for Mycobacterium tuberculosis by Ziehl Neelsen staining 
method. Among them, 11 samples (11%) were found to be positive for Acid 
Fast Bacilli [Table:9] 
        In a study by Purohit et al (2000), an early diagnosis of pulmonary 
tuberculosis was made in 13%  by positive microscopy for AFB on BAL.[99] 
In another study by Getachew et al Mycobacterium tuberculosis was isolated 
in 19% sample of BAL.[57] 
81 
 
         The Antibiogram performed for all the bacterial isolates in this study 
by Kirby-Bauer Disc Diffusion Method showed the Klebsiella spp. with 
83.3% sensitivity to Amikacin, 54.2% sensitivity to Cefotaxime, 66.7% to 
Ceftazidime, 79.2% to Ciprofloxacin and 100% to Imipenem [Table:11] 
          The second most common bacilli Pseudomonas aeruginosa showed 
88.9% sensitivity to Amikacin, 55.6% to Cefotaxime and 100% to 
Imipenem. Acinetobater spp. showed 100% sensitivity to Amikacin and 
Imipenem. 
         All the isolates were 100% sensitive to Imipenem. The next most 
effective drug was found to be Amikacin with 94% sensitivity. 
      These observations were similar to the studies of Bartlett JG et al 
(2002) and Sharma et al (2006), where Imipenem showed 100% sensitivity 
and Amikacin was effective against 93 to 95% isolates.[8,109] 
       Out of the 6 strains of Staphylococcus aureus, 2 strains (33.3%) 
showed sensitivity to Oxacillin (1µg disc) by disc diffusion method; 
Methicillin sensitive Staphylococcus aureus (MSSA) strains were also 
sensitive to Penicillin (100%), Ampicillin (100%), Cotrimoxazole (100%), 
Ciprofloxacin (100%), Amikacin (100%) and Erythromycin (100%) 
[Table:10] 
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       The other 4 strains (66.7%) of Staphylococcus aureus showed 
resistance to Oxacillin (1µg disc) (MRSA). All the 6 isolates of 
Staphylococcus aureus were sensitive to Vancomycin (100%). 
          Among the gram negative bacilli, 42% of Klebsiella pneumoniae, 
50% of Klebsiella oxytoca, 20% of Escherichia coli and 25% of Proteus 
vulgaris were found to be Extended Spectrum β Lactamase producers by 
screening method [Table:12] 
          By Phenotypic Confirmatory Disc Diffusion Test, 33.3% of 
Klebsiella pneumoniae, 33.3% of Klebsiella oxytoca, 20% of Escherichia 
coli and 25% of Proteus vulgaris were confirmed as ESBL producers 
[Table:13] 
       Jarlier et al reported that Klebsiella pneumoniae (48%) was the most 
frequent ESBL producing organism followed by Escherichia coli (16.8%) in 
Bronchoalveolar lavage which correlates well with our study.[71] In another 
study by Baker et al 2006, Klebsiella pneumoniae was found to be the most 
common ESBL producing organism. 
          Among the 11 Candida spp. screened by Disc Diffusion Method in 
this study, all the isolates of both Candida albicans and Candida tropicalis 
showed 100% sensitivity to Amphotericin B and Itraconazole. Fluconazole 
resistance was observed in 2 isolates (66.7%) of Candida tropicalis. 
[Table:14] 
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         A study by Law D et al reported that 48% of Candida tropicalis in his 
study was resistant to fluconazole.[80] Rex et al (1996), reported that all the 
isolates of Candida albicans in his study were sensitive to Amphotericin B 
and observed 54% resistance to Fluconazole for Candida tropicalis.[102]                           
     In the present study Antifungal susceptibility was performed on the 3 
isolates of Aspergillus spp. for Amphotericin B by Broth microdilution 
method. It was observed that all the 3 isolates (100%) of Aspergillus spp. 
were sensitive to Amphotericin B with MIC ≤ 1 µg/ml [Table:15] 
      This result correlates well with the study by Espinel-Ingroff et al 
(2007), where the sensitivity of Aspergillus spp. to Amphotericin B was 
found to be 100%.[52] In a study by Bez et al 2002, Aspergillus flavus showed 
100% susceptibility to Amphotericin B.[16] 
          In evaluating the screening tests for rapid diagnosis of the bacterial 
and fungal isolates in bronchoalveolar lavage, Gram’s stain examination and  
10% Potassium hydroxide (KOH) mount of the BAL fluid were analysed.   
      In the present study, the Gram’s stain showed sensitivity of 79.6% and 
specificity of 95.6% (Table:16). Prekates et al (1998), reported 77% 
sensitivity and 87% specificity of Gram’s stain examination of 
Bronchoalveolar lavage.[98] In a study by Allaouchiche et al (2007), the 
sensitivity of Gram’s stain was 90.2% and specificity was 73.7%.[2] 
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      In this study 10% KOH mount examination for fungal elements 
showed sensitivity of 93.3% (Table-17). This correlates with the study of 
Vajpayee.R.B, et al, (1993), which revealed 94.3% sensitivity of 10% KOH 
mount examination. Bharathi M J et al (2007) reported 99% sensitivity for 
10% KOH mount.[118,17] 
    The results of the present study showed the vital role of Gram’s stain 
examination and 10% KOH mount in the diagnosis of Lower respiratory 
tract infections. Although culturing of microbial pathogens is considered to 
be the gold standard, direct microscopic evaluation of smears provide 
immediate information about the aetiological agents and aid in early 
initiation of antimicrobial therapy. 
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SUMMARY 
? Totally 100 samples of Bronchoalveolar fluid were analysed in detail. 
Bacterial and fungal isolates were found in 60 (60%) samples. 
? Male preponderance of lower respiratory tract infections was observed 
in this study. 
? The age group most commonly affected was between 41-60 years.  
? Pneumonia was found to be the most common lower respiratory tract 
infection. 
? Majority of the isolates were bacterial (78.3%) with gram negative 
bacilli (68.1%) being the most common. 
? Among the gram negative bacilli, Klebsiella spp. (Klebsiella 
pneumonia and Klebsiella oxytoca) (33.3%) was the most common 
followed by Pseudomonas aeruginosa and Acinetobacter baumanii 
(16.7% each) 
? Fungal isolates were less common (21.7%). The predominant fungal 
isolate was Candida albicans followed by Aspergillus spp. 
? Acid Fast Bacilli were found in 11% of the total samples. 
? All the bacterial isolates were sensitivie to Imipenem and majority of 
the isolates were sensitive to Amikacin. 
? Among the Staphylococcus aureus, 33.3% was methicillin sensitive 
and 66.7% was methicillin resistant. 
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? All the 4 MRSA strains were sensitive to Vancomycin. 
? The incidence of ESBL producing Klebsiella spp. was 33.3% and 
Escherichia coli was 20%. 
? All the isolates of Candida spp. were sensitive to Amphotericin B and 
Itraconazole. 66.7% of Candida tropicalis showed resistance to 
Flucanazole by Disc Diffusion method. 
? All the isolates of Aspergillus spp. were sensitive to Amphotericin B 
by Broth Microdilution method. 
? Gram’s stain and 10% KOH mount procedures were found to be 
highly sensitive as rapid screening tests for isolating the bacterial and 
fungal isolates in Bronchoalveolar lavage. 
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CONCLUSION 
Lower respiratory tract infections are the major cause of morbidity and 
mortality worldwide. But the etiological agents were not determined in 50% 
of cases despite extensive diagnostic testings. Nowadays, analysis of 
Bronchoalveolar lavage plays a definite role in diagnosing pulmonary 
infections. On analysing the BAL fluid, Klebsiella spp. and Candida spp. 
were the most common bacterial and fungal isolates respectively. From the 
present study, the vital role of microbiological analysis of BAL fluid is 
clearly evident since the clinical features alone are not adequate to confirm 
infections. A simple Gram’s stain and KOH preparation were highly 
beneficial as rapid screening tests for diagnosis. Antimicrobial susceptibility 
testing was done for the bacterial and fungal isolates. Precise identification 
of the causative organisms and timely institution of appropriate antimicrobial 
therapy based on the prevailing sensitivity pattern of the bacterial and fungal 
isolates could reduce the morbidity and mortality of lower respiratory tract 
infections. 
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PROFORMA 
 
S.No. :                                Date:                            I.P./O.P.No.: 
 
Name :                                Age/Sex:                     Occupation: 
Address : 
Presenting Complaints:                                           Duration: 
Number of days hospitalized: 
Provisional Diagnosis: 
Date of bronchoscopy: 
H/O present illness: 
• Fever 
• Cough with expectoration 
• Breathlessness 
• Weight loss 
• Haemoptysis 
H/O past illness: 
• Similar illness before 
• Tuberculosis 
• Diabetes 
• Hypertension 
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• Smoking 
• Alcohol intake 
• Blood transfusion 
Family history: 
H/O contact with known case of tuberculosis 
Laboratory evaluation: 
• X ray findings 
• CT findings 
• MRI findings 
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
 
ABBREVIATIONS 
 
BAL – Bronchoalveolar lavage 
MDR – multidrug resistant 
CAP – Community acquired pneumonia 
HCAP – Health care associated pneumonia 
HAP – Hospital acquired pneumonia 
VAP – Ventilator associated pneumonia 
COPD – Chronic obstructive pulmonary disease 
HIV – Human immunodeficiency virus 
AIDS – Acquired immunodeficiency syndrome 
PSB – Protected specimen brush 
LRTI – Lower respiratory tract infection 
FOB – Fiberoptic bronchoscopy 
PTB – Pulmonary tuberculosis 
KOH – Potassium hydroxide 
LPCB – Lactophenol cotton blue 
CLSI – Clinical and laboratory standards institute 
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APPENDIX 
 
A. STAINS AND REAGENTS 
I. 10% KOH 
              Potassium hydroxide l0g 
              Glycerol – l0ml 
              Distilled water - 80ml 
II. Gram staining 
               Methyl violet (2%) – l0g Methyl violet in l00ml absolute  
                                               Alcohol in 1litre of distilled water                  
                                               (Primary stain) 
                Grams Iodine – l0g Iodine in 20g KI (fixative) 
                Acetone – Decolourising agent 
                Carbol fuchsin 1% – Secondary stain 
III. Lactophenol cotton blue stain 
                 Lactic acid - 20 ml 
                 Phenol - 20ml 
                 Cotton blue (dye) - 0.5g 
                 Glycerol - 40ml 
                  Distilled water - 20ml. 
 
 
92 
 
Culture Media 
1. Mac Conkey agar 
                   Peptone                                    -             20g 
                   Sodium taurocholate                -               5g 
                   Distilled Water                          -              1 ltr 
                   Agar                                          -             20g 
                   2% neutral red in 50% ethanol -             3.5ml 
                   10% lactose solution                 -             l00mI 
                 Dissolve peptone and taurocholate in water by heating. Add agar 
and dissolve it in steamer. Adjust pH to 7.5. Add lactose and neutral red 
shake well and mix. Heat in free steam (100°C) for 1 hour, then autoclave at 
115°C for 15 minutes. 
 
2. Blood agar (5% sheep blood agar) 
                     Peptone                    -          l0g 
                     Nacl                          -          5g 
                     Distilled water           -         1 Ltr 
                     Agar                          -         10g 
               Dissolve ingredients in distilled water by boiling, and add 5% 
sheep blood (sterile) at 55°C adjust pH to 7.4. 
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3.Chocolate Agar 
                      Sterile defibrinated blood      -         10 ml 
                      Nutrient Agar (melted)           -         100 ml 
           When the temperature was about 75°C, sterile blood was added with 
constant agitation. After addition of blood, kept in water bath and heating 
was continued till the blood changed to chocolate colour. Cooled to about 
50° C and poured about 15ml into petri dishes with sterile precaution. 
4. Sabouraud’s Dextrose Agar With Antibiotics 
          Composition of Sabouraud’s Dextrose Agar (Emmons Modification) 
                      Dextrose           -              20 gm 
                      Peptone            -              10 g 
                      Agar                  -              20 g 
                      Distilled water   -               1000 ml 
                      Final pH            -               6.9 
         The ingredients are dissolved by boiling. Gentamycin was 
dissolved in 10 ml of 95% alcohol and added to boiling medium. 
Autoclave at 121°C for 15 minutes, dispense in tubes and allow to cool in 
slanted position. 
 
5. Mueller- Hinton Agar 
                      Beef infusion                   -         300ml 
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                      Caesein hydrolysate       -          17.5g 
                      Starch                             -           1.5g 
                      Agar                               -           10g 
                       Distilled water                 -           1ltr 
                       pH                                  =           7.4 
         Sterilise by autoclaving at 1210C for 20 mins 
6. RPMI 1640 Broth 
               Commercially purchased RPMI 1640 media was dissolved in 
1000ml of sterile distilled water. The pH was adjusted to 7.0 
The medium was sterilized by filtering through a sterile membrane filter 
with a porosity of 0.22 microns. 
7.Cornmeal Agar 
                      Cornmeal         -         40g 
                      Agar                 -         15g 
                      Water               -          1 litre 
             Boil the cornmeal in 1 litre of water for 60 min.Filter through muslin 
and add the agar. Steam to dissolve, dispense in required amounts and 
autoclave at 115° C for 30min. allow to cool to 50°C and pour approximately 
20 ml amounts into Petri dishes. 
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8. Sugar Fermentation Medium 
                      Peptone                     -            15g 
                      Andrade’s indicator    -            10 ml 
                      Sugar to be tested      -            20g 
                      Water                          -            1litre 
           Andrade’s indicator is prepared from 0.5% aqueous acid fuchsin to 
which sufficient 1M sodium hydroxide has been added to turn the colour of 
the solution yellow. 
            Dissolve the peptone and Andrade’s indicator in 1litre of water and 
add 20g of the sugar; sugars to be tested generally include glucose ,sucrose, 
lactose and maltose. Distribute 3ml amounts in standard test tubes containing 
an inverted Durham tube. Sterilize by steaming at 100 degree C for 30 min 
on 3 consecutive days. 
9. Sugar Assimilation Agar 
                  Basal medium I 
                  Yeast nitrogen base(Difco) 
                  Agar 
                  Water    
     Steam to dissolve and dispense in 10ml amounts in universal containers. 
Autoclave at 115 degree C for 15min. 
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MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION OF 
BACTERIA 
1.Oxidase Reagent 
                 Tetra methyl p-phenelene diamine dihyrochloride- 
                  1% aqueous solution. 
2.Catalase 
                  3% hydrogen peroxide 
3.Indole test 
                  Kovac’s reagent 
                  Amyl or isoamyl alcohol                     - 150ml 
                  Para dimethyl amino benzaldehyde  - 10g 
                  Concentrated hydrochloric acid        -  50ml 
       Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in 
small quantities and store in the refrigerator. Shake gently before use. 
4.Christensen’s Urease test medium 
                  Peptone                                           -        1g 
                  Sodium chloride                               -      5g 
                  Dipotassium hydrogen phosphate  -         2g 
                  Phenol red                                       -        6ml 
                  Agar                                                 -       20g 
                  Distilled water                                  -       1ltr 
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                  10% sterile solution of glucose        -           l0ml 
                  Sterile 20% urea solution                 -          l00ml 
        Sterilize the glucose and urea solutions by filtration. Prepare the basal 
medium without glucose and urea, adjust to pH 6.8-6.9 and sterilize by 
autoclaving in a flask at 121°C for 30min. Cool to about 50°C, add the 
glucose & urea, and tube the medium as slopes. 
5.Simmon’s Citrate Medium 
                  Koser’s medium                   -       1 ltr 
                  Agar                                     -       20g 
                  Bromothymol blue 0.2%     -       40ml 
           Dispense, autoclave’ at 121°C for 15 min and allow to set as slopes 
6.Triple Sugar Iron medium 
                   Beef Extract               -         3g 
                   Yeast extract              -          3g 
                    Peptone                      -         20g 
                    Glucose                      -          1g 
                    Lactose                      -         10g 
                    Sucrose                     -          10g 
                    Ferric citrate               -         0.3g 
                    Sodium chloride          -          5g 
                    Sodium thiosulphate   -          0.3g 
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                    Agar                            -           12g 
                     Phenol red 0.2% solution -      12ml 
                     Distilled water                   -      1 ltr 
               Heat to dissolve the solids, add the indicator solution, mix and tube. 
Sterilize at 121°C for 15 min and cool to form slopes with deep butts. 
7.Glucose phosphate broth 
                      Peptone                                               -        5g 
                      Dipotassium hydrogen phosphate       -        5g 
                      Water                                                  -        1 ltr 
                      Glucose 10% solution                        -        50ml 
           Dissolve the peptone and phosphate and adjust the pH to 7.6. Filter 
dispense in 5ml amounts and sterilize at 121°c for 15min. Sterilize the 
glucose solution by filtration and add 0.25ml to each tube. 
Methyl Red Reagent 
                       Methyl Red - 10mg 
                       Ethyl alcohol - 30ml 
                       Distilled water - 20ml 
Voges Proskauer Reagent 
                        Reagent A: Alpha naphthol - 5g 
                                            Ethyl alcohol - 100ml 
                         Reagent B: Potassium hydroxide - 40g 
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                                            Distilled water - 100ml 
8.Peptone water fermentation test medium. 
                To the basal medium of peptone water, add sterilised sugars of 1% 
indicator bromothymol blue with Durham’s tube. 
Basal medium - peptone water 
Sugar solutions: 
Sugar - 1ml 
Dislilled water - l00ml 
pH = 7.6. 
9.Mannitol motility medium 
                     Agar                         -           5g 
                     Peptone                  -             1g 
                     Potassium nitrate    -             1g 
                     Mannitol                 -             2g 
                     Phenol red indicator 
                     Distilled water - l000ml 
                     pH = 7.2 
10. Potassium Nitrate Broth 
                     Potassium nitrate (KN03)       -          0.2gm 
                     Peptone                                   -          5.0gm 
                     Distilled water                         -          100ml          
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The above ingredients were mixed and transferred into tubes in 5 
ml amount and autoclaved. 
11. Phenyl Alanine Deaminase Test 
                      Yeast Extract 3g  
                      Dl-Phenylalamine 2 g      
                      Disodium hydrogen phosphate lg   
                      Sodium Chloride - 5 g 
                      Agar 12g  
                       Distilled water - 1 lr 
pH adjusted to 7.4, distributed in tubes and sterilized by 
autoclaving at 121° C for 1 5 minutes, allowed to solidify as long slopes. 
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